Since several genes involved in the initiation, promotion and tumour progression are regulated by NF-kB and its activation suppresses apoptosis and promotes cell proliferation[16,54], the rational design of treatments that decrease NF-kB activity is a good strategy to treat malignancies, as observed here. The gene discussed is NFKB1; the disease is neoplasm.